Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856331 · ClinicalTrials.gov registry record · Phase 2
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT05856331 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 99 participants.
The verdict
NCT05856331, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
Interventions
- DRUG SAR447537
- DRUG Zemaira
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2025-08-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05856331
The ClinicalTrials.gov registry entry for NCT05856331 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAR447537 is the first listed.
NCT05856331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05856331 about?
NCT05856331 is a clinical study titled "Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema". Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
What is the current status of trial NCT05856331?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2023-10-12. Estimated completion is 2025-08-06.
What interventions are being tested in trial NCT05856331?
The interventions under investigation include: SAR447537 (DRUG), Zemaira (DRUG).
Who is sponsoring clinical trial NCT05856331?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.